- ASSISTANT PROFESSOR Genetics and Genomic Sciences
Ph.D., McGill University
- Dr. Savic obtained his Ph.D. degree from Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University, Montreal, Canada. He then completed postdoctoral training at Mount Sinai in laboratories of world experts in diabetes (Dr. LeRoith); liver diseases (Drs. Friedman and Llovet); and lysosomal storage disorders (Dr. Schuchman). Working with clinician/translational scientists enabled Dr. Savic to experience firsthand the processes and challenges of progression of small molecule drugs and biologics from laboratory and pre-clinical research to clinical trials. Dr. Savic also conducted advanced pre-clinical trials of select clinical grade enzymes, e.g., those used in treatment of rare lysosomal storage disorders, repurposed for potential use as adjuvant treatments of cancer.
Technology Development Fund Award
Academic Gold Medal
Governor General of Canada
Sourkes Prize in Pharmacology
Pharmacology & Therapeutics, McGill University
ResearchCentral point of our research is integrating advances in pharmacology, systems biology, and bioinformatics into pre-clinical research and drug development. We are exceptionally interested in acquiring competencies for enhancing the use of Big Data in developing novel therapeutic and diagnostic treatments. In addition, the principles of pharmacology, nanotechnology, nanomedicine and pharmaceutics are considered, as appropriate, in achieving these goals. Teamwork with scientists from academia, industry, hospitals and other research centers of excellence is an essential component of these endeavors. The overall goal is to enable authentic benefits to patients.
Savic R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science (New York, N.Y.) 2003 Apr; 300(5619).
Savić R, Azzam T, Eisenberg A, Maysinger D. Assessment of the integrity of poly(caprolactone)-b-poly(ethylene oxide) micelles under biological conditions: a fluorogenic-based approach. Langmuir : the ACS journal of surfaces and colloids 2006 Apr; 22(8).
Savić R, Eisenberg A, Maysinger D. Block copolymer micelles as delivery vehicles of hydrophobic drugs: micelle-cell interactions. Journal of drug targeting 2006 Jul; 14(6).
Savić R, Azzam T, Eisenberg A, Nedev H, Rosenberg L, Maysinger D. Block-copolymer micelles as carriers of cell signaling modulators for the inhibition of JNK in human islets of Langerhans. Biomaterials 2009 Jul; 30(21).
Villanueva A, Savic R, Llovet JM. Lymphotoxins: new targets for hepatocellular carcinoma [editorial]. Cancer cell 2009 Oct; 16(4).
Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, Schwartz M, Bruix J, Waxman S, Friedman SL, Golub T, Mazzaferro V, Llovet JM. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011 May; 140(5).
Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Sep; 18(18).
Savić R, Schuchman EH. Use of acid sphingomyelinase for cancer therapy. Advances in cancer research 2013; 117.
Savić R, He X, Fiel I, Schuchman EH. Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer. PloS one 2013; 8(5).
Savic R, Zheng J, Allen C, Maysinger D. Nanomedicines Coming of Age: Recent Developments in Nanoneuroscience and Nano-Oncology. In: Polymeric Biomaterials: 2 Volume Set, Third Edition (Eds. S. Dumitriu and V.I. Popa). Boca Raton, FL, CRC Press, Taylor and Francis Group (2013);.
Savic R, Maysinger D. Nanomedicine in Diabetes: Using Nanotechnology in Prevention and Management of Diabetes Mellitus. In: Handbook of Nanotoxicology, Nanomedicine and Stem Cell Use in Toxicology (Eds. S. C. Sahu and D. A. Casciano). Chichester, UK, John Wiley & Sons, Ltd. (2014);.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Savic did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.
Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.
Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.